The Margin the Market Has Decided to Ignore
Prestige Consumer Healthcare has spent two decades doing something quietly difficult: buying unglamorous drugstore brands, Clear Eyes, Chloraseptic, Monistat, and...
Regeneron: The Drug That Keeps Growing, and the Trial That Didn’t
Regeneron spent most of the 2010s as a one-drug story, riding EYLEA's dominance in eye disease to a valuation that...
Evidence Sheet: Starbucks (SBUX)
The standing BullScope yardsticks for Starbucks, computed from official filings and refreshed with each new edition.
Evidence Sheet: Nike (NKE)
The standing BullScope yardsticks for Nike, computed from official filings and refreshed with each new edition.
Gilead’s Ledger: A Business Growing Faster Than Its Balance Sheet Suggests
Six years ago, Gilead Sciences was a company with a problem it couldn't quite name. Its hepatitis C drugs had...
AbbVie at $257: The Price That Needs Everything to Go Right
Humira once generated more annual revenue than the entire GDP of a small country. Then, in January 2023, the first...
Evidence Sheet: Netflix (NFLX)
The standing BullScope yardsticks for Netflix, computed from official filings and refreshed with each new edition.
Trulieve: A $403 Million Loss That Isn’t What It Looks Like, and a Profit That Might Be
First, the shape of it The most recent filing shows a headline loss bigger than the company earns in a...
Prices at the Factory Gate Are Running Hot. Wages Are Not. Something Has to Give.
Five years ago, the word "transitory" was the most expensive word in American economic policy. The Federal Reserve used it...
Bio-Techne at $72.25: The Price That Was Already Agreed Upon
Before anything else Merck KGaA agreed in June to buy Bio-Techne for $73 per share in cash, and the stock...
BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.